SURVYR

RGEN

Repligen Corporation
$175.80
−$4.37 (2.43%)Oct 27 close
Health CareS&P 400 CompareTechnicals
1M3M6M1Y2Y
-37%-22%-7%+8%+23%Oct 2025Oct 2026Apr 202652w high $198.8752w low $100.99
RGENSPY
Wall St. Highest PT $235.00 (+33.7%) Wall St. Avg PT $199.70 (+13.6%)
$103$138$172$207$242POC $165Hi $235Avg $200
Underwater Drawdown %Max DD -40.3%Current -9.6%
0.0%-40.3%
Relative Strength vs SPY-4.4% vs SPYUnderperforming
+52%0%-52%
1W
−$3.08 (1.72%)
1M
−$13.88 (7.32%)
3M
+$30.46 (20.96%)
6M
+$58.37 (49.71%)
YTD
+$11.94 (7.29%)
1Y
+$14.70 (9.12%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
20 analysts · mean score 1.50
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$175.80
Average target$199.70
+$23.90 (+13.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$160.00
Median$199.70
High$235.00
12-month Wall Street target range

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$11.4B
P/E (last 12 months)246.6
P/E (next 12 months, estimated)66.7
52-week range$100.99 – $198.87
Revenue growth (latest quarter vs a year ago)+11.9%
Dividend yieldNo dividend
Analyst consensusStrong Buy (20)
Average analyst price target$199.70 (+14%)

What they do

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Healthcare · Medical Instruments & Supplies
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
63rd percentile in sector
B-
12-1 return: +29.0%
Percentile within its GICS sector across the S&P 1500.
Growth
65th percentile in sector
B
Revenue growth (YoY): +11.9%
Percentile within its GICS sector across the S&P 1500.
Value
4th percentile in sector
F
Forward E/P: 1.5% · EBITDA/EV: 1.5%
Percentile within its GICS sector across the S&P 1500.
Profitability
34th percentile in sector
C-
Profit margin: +5.3% · Return on equity: +2.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RGEN earningsReported Oct 27, 2026▲ Above estimates
Results · Before the open
EPS actual$0.53
EPS estimate$0.46
Surprise+14.6%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Last 4 quarters · EPS vs estimate
Oct 27, 2026$0.53est $0.46+14.6%Above estimates
Jul 28, 2026$0.54est $0.45+20.4%Above estimates
May 5, 2026$0.48est $0.39+22.9%Above estimates
Feb 24, 2026$0.49est $0.44+10.4%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 17:56:26 ET
25-0225-0425-0725-1026-0226-0526-0726-100.000.54
EstimateActual (beat)Actual (miss)

News & catalysts

More news
Repligen (RGEN) Q3 2026 Earnings Call Transcript
Nasdaq · 11h ago
Repligen (RGEN) files 8-K: results
SEC 8-K · 16h ago
Insider trades
Loeillot Olivier
Director, Chief Executive Officer · 2026-10-05
Sell
$798.4K
Loeillot Olivier
Director, Chief Executive Officer · 2026-10-05
Sell
$238.3K
Loeillot Olivier
Director, Chief Executive Officer · 2026-09-24
Sell
$863.0K
Loeillot Olivier
Director, Chief Executive Officer · 2026-09-24
Sell
$1.6M
Loeillot Olivier
Director, Chief Executive Officer · 2026-09-21
Sell
$976.7K
Loeillot Olivier
Director, Chief Executive Officer · 2026-09-04
Sell
$503.5K
Loeillot Olivier
Director, Chief Executive Officer · 2026-08-20
Sell
$976.7K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 17:56:26 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026